Zydus Cadila Receives Us Fda Approval For Mesalamine Er Capsules
Zydus Cadila Has Received Final Approval From The Us Food And Drug Administration (Fda) To Market Mesalamine Extended-Release Capsules In The Strength Of 0.375 G.Mesalamine Extended-Release Capsules Are Indicated For The Maintenance Of Remission Of Ulcerative Colitis In Adults.The Drug Will Be Manufactured At The Group&Rsquo;S Formulation Manufacturing Facility At The Sez, Ahmedabad.The Group Now Has 320 Approvals And Has So Far Filed Over 400 Andas Since The Commencement Of The Filing Process In Fy 2003-04.
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!